Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Wennström, Malin ^a   Hall, Sara ^a   Nägga, Katarina ^a   Londos, Elisabet ^a   Minthon, Lennart ^a   Hansson, Oskar ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; INTERLEUKIN 6; TAU PROTEIN; IL6 PROTEIN, HUMAN; SNCA PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHEMOLUMINESCENCE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIPLEX ELECTROCHEMILUMINESCENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNUCLEINOPATHY; VERY ELDERLY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOMARKERS; COGNITION; FEMALE; HUMANS; INTERLEUKIN-6; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84942940978     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0145-y     Document Type: Article

References (62)

1. Nakanishi M, Niidome T, Matsuda S, Akaike A, Kihara T, Sugimoto H. Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur J Neurosci. 2007;25:649-58. doi:10.1111/j.1460-9568.2007.05309.x.
2. Oh J, McCloskey MA, Blong CC, Bendickson L, Nilsen-Hamilton M, Sakaguchi DS. Astrocyte-derived interleukin-6 promotes specific neuronal differentiation of neural progenitor cells from adult hippocampus. J Neurosci Res. 2010;88:2798-809. doi:10.1002/jnr.22447.
3. Peng YP, Qiu YH, Lu JH, Wang JJ. Interleukin-6 protects cultured cerebellar granule neurons against glutamate-induced neurotoxicity. Neurosci Lett. 2005;374:192-6. doi:10.1016/j.neulet.2004.10.069.
4. Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M, Garotta G, et al. Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol Cell Neurosci. 2004;25:301-11. doi:10.1016/j.mcn.2003.10.022.
5. Wang XC, Qiu YH, Peng YP. Interleukin-6 protects cerebellar granule neurons from NMDA-induced neurotoxicity. Sheng Li Xue Bao. 2007;59:150-6.
6. Chao CC, Hu S, Ehrlich L, Peterson PK. Interleukin-1 and tumor necrosis factor-α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun. 1995;9:355-65.
7. A dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1345-56. doi:10.1152/ajpregu.00268.2005.
8. Steffensen SC, Campbell IL, Henriksen SJ. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res. 1994;652:149-53.
9. Vallières L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci. 2002;22:486-92.
10. Samuelsson AM, Alexanderson C, Mölne J, Haraldsson B, Hansell P, Holmäng A. Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat. J Physiol. 2006;575:855-67. doi:10.1113/jphysiol.2006.111260.
11. Balschun D, Wetzel W, Del Rey A, Pitossi F, Schneider H, Zuschratter W, et al. Interleukin-6: a cytokine to forget. FASEB J. 2004;18:1788-90. doi:10.1096/fj.04-1625fje.
12. Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci. 2006;26:10709-16. doi:10.1523/JNEUROSCI.3376-06.2006.
13. Adriaensen W, Matheï C, Vaes B, van Pottelbergh G, Wallemacq P, Degryse JM. Interleukin-6 predicts short-term global functional decline in the oldest old: results from the BELFRAIL study. Age (Dordr). 2014;36:9723. doi:10.1007/s11357-014-9723-3.
14. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59:710-3. doi:10.2337/db09-1163.
15. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology. 2002;59:371-8.
16. Wright CB, Sacco RL, Rundek T, Delman J, Rabbani L, Elkind M. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. J Stroke Cerebrovasc Dis. 2006;15:34-8. doi:10.1016/j.jstrokecerebrovasdis.2005.08.009.
17. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66:287-92. doi:10.1016/j.biopsych.2009.01.030.
18. Yu SY, Zuo LJ, Wang F, Chen ZJ, Hu Y, Wang YJ, et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 2014;14:113. doi:10.1186/1471-2377-14-113.
19. Huell M, Strauss S, Volk B, Berger M, Bauer J. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol. 1995;89:544-51.
20. Hull M, Strauss S, Berger M, Volk B, Bauer J. The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res. 1996;78:37-41.
21. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403. doi:10.1016/S0140-6736(06)69113-7.
22. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol. 2005;109:141-50. doi:10.1007/s00401-004-0919-y.
23. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-72.
24. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease - associations with depression, fatigue, and cognitive impairment. Brain Behav Immun. 2013;33:183-9. doi:10.1016/j.bbi.2013.07.007.
25. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228-34. doi:10.1016/S1474-4422(06)70355-6.
26. Nascimento CM, Pereira JR, de Andrade LP, Garuffi M, Talib LL, Forlenza OV, et al. Physical exercise in MCI elderly promotes reduction of proinflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res. 2014;11:799-805.
27. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1β, interleukin-6, and tumor necrosis factor-α: centralmonoamine, corticosterone, and behavioral variations. Neuropsychopharmacology. 2000;22:566-80. doi:10.1016/S0893-133X(99)00166-9.
28. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768-74. doi:10.1212/WNL.0b013e3181b6bb95.
29. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1β, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:788-9.
30. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995;202:17-20.
31. 1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett. 2005;383:12-6. doi:10.1016/j.neulet.2005.03.051.
32. Martínez M, Fernández-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations. Brain Res. 2000;869:216-9.
33. Yamada K, Kono K, Umegaki H, Iguchi A, Fukatsu T, Nakashima N, et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neurosci Lett. 1995;186:219-21.
34. Engelborghs S, De Brabander M, De Cree J, D'Hooge R, Geerts H, Verhaegen H, et al. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int. 1999;34:523-30.
35. März P, Heese K, Hock C, Golombowski S, Müller-Spahn F, Rose-John S, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 1997;239:29-32.
36. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol. 2003;60:1218-22. doi:10.1001/archneur.60.9.1218.
37. Nielsen H, Ek D, Avdic U, Orbjörn C, Hansson O, The Netherlands Brain Bank, et al. NG2 cells, a new trail for Alzheimer's disease mechanisms? Acta Neuropathol Commun. 2013;1:7.
38. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013;8:e53250. doi:10.1371/journal.pone.0053250.
39. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
41. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology. 1996;47:1113-24.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
43. Wennström M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis. 2012;29:125-32. doi:10.3233/JAD-2012-111655.
44. Shepherd CE, Thiel E, McCann H, Harding AJ, Halliday GM. Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies. Arch Neurol. 2000;57:817-22.
45. Kálmán J, Juhász A, Laird G, Dickens P, Járdánházy T, Rimanóczy A, et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand. 1997;96:236-40.
46. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-70. doi:10.1146/annurev.med.51.1.245.
47. Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, et al. Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation. 2001;9:209-17.
48. Nelson PT, Schmitt FA, Jicha GA, Kryscio RJ, Abner EL, Smith CD, et al. Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol. 2010;257:1875-81. doi:10.1007/S00415-010-5630-4.
49. Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther. 2014;6:25. doi:10.1186/alzrt255.
50. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, et al. Differential levels of α-synuclein, β-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2010;81:608-10. doi:10.1136/jnnp.2009.197483.
51. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230-40. doi:10.1016/S1474-4422(11)70014-X. A published erratum appears in Lancet Neurol. 2011;10:297.
52. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, et al. Cerebrospinal fluid tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. 2011;26:1428-35. doi:10.1002/mds.23670.
53. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. α-Synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord. 2012;26:213-6. doi:10.1097/WAD.0b013e31823899cc.
54. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213:315-25. doi:10.1016/j.expneurol.2008.06.004.
55. Sako W, Murakami N, Izumi Y, Kaji R. Reduced α-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord. 2014;29:1599-605. doi:10.1002/mds.26036.
56. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2009;1251:1-6. doi:10.1016/j.brainres.2008.11.055.
57. Spies PE, Melis RJ, Sjögren MJ, Rikkert MG, Verbeek MM. Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders. J Alzheimers Dis. 2009;16:363-9. doi:10.3233/JAD-2009-0955.
58. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs normal subjects and patients with Alzheimer's disease. PLoS One. 2013;8, e81654. doi:10.1371/journal.pone.0081654.
59. Ingham V, Williams A, Bate C. Glimepiride reduces CD14 expression and cytokine secretion from macrophages. J Neuroinflammation. 2014;11:115. doi:10.1186/1742-2094-11-115.
60. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19:533-42. doi:10.1096/fj.04-2751com.
61. Garcia-Esparcia P, Llorens F, Carmona M, Ferrer I. Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent. Brain Pathol. 2014;24:584-98. doi:10.1111/bpa.12137.
62. Müller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand. 1998;98:142-4.